ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic unive… Read more
ViGenCell Inc. (308080) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.025x
Based on the latest financial reports, ViGenCell Inc. (308080) has a cash flow conversion efficiency ratio of -0.025x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.24 Billion) by net assets (₩49.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ViGenCell Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ViGenCell Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ViGenCell Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ViGenCell Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hazer Group Limited
PINK:HZRGF
|
-0.072x |
|
Creditwest Faktoring AS
IS:CRDFA
|
-0.586x |
|
O3 Mining Inc
OTCQX:OIIIF
|
0.001x |
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
0.018x |
|
Pyrum Innovations AG
OL:PYRUM
|
-0.116x |
|
Pulmonx Corp
NASDAQ:LUNG
|
-0.151x |
|
Naked Wines plc
PINK:MJWNY
|
0.096x |
|
Shenwan Hongyuan (H.K.) Limited
F:WAY
|
0.137x |
Annual Cash Flow Conversion Efficiency for ViGenCell Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of ViGenCell Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩58.03 Billion | ₩-10.90 Billion | -0.188x | +12.08% |
| 2023-12-31 | ₩71.49 Billion | ₩-15.27 Billion | -0.214x | -72.64% |
| 2022-12-31 | ₩89.64 Billion | ₩-11.09 Billion | -0.124x | -63.12% |
| 2021-12-31 | ₩104.89 Billion | ₩-7.95 Billion | -0.076x | -131.54% |
| 2020-12-31 | ₩-34.07 Billion | ₩-8.19 Billion | 0.240x | +105.77% |
| 2019-12-31 | ₩-25.32 Billion | ₩-2.96 Billion | 0.117x | -- |